Dianthus Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 82.38 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 4.61B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio...